This has formed the basis of the expert American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) panel in 2007 to develop guidelines to improve the accuracy of HER2 testing in breast cancer [7]. The gene discussed is ERBB2; the disease is breast cancer.